AUG 14, 2026 · PHASE 1 TRIAL
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
ClinicalTrials.gov
Phase 1 trial of a novel combination of KRAS-targeted TCR-engineered T-cells with therapeutic vaccine in metastatic solid cancers; registry record with no results posted; early-stage feasibility and safety assessment.
Reported
Planned enrollment210
PhasePhase 1
Primary outcome: tumor responseComplete response (CR) and/or partial respo…